Physician profile
Mayank S Pathak
NPI 1114959475
$32,810.20
in general payments reported to CMS, 2019-2025
83 companies · $5,990 in 2025
The $5,990 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,314 · 2020: $3,167 · 2021: $4,179 · 2022: $4,652 · 2023: $4,813 · 2024: $5,695 · 2025: $5,990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,394.40 |
| Education | $103.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,269.97 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $2,489.47 | 2019-2025 | |
| Biogen, INC. | $2,325.25 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Sk Life Science, INC. | $1,390.01 | 2020-2025 | Xcopri |
| Ucb, INC. | $1,349.89 | 2019-2025 | Rystiggo, Briviact, Nayzilam |
| Alexion Pharmaceuticals, INC. | $1,227.76 | 2019-2025 | Ultomiris, Soliris |
| Eisai INC. | $1,104.11 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $1,008.79 | 2020-2025 | Ingrezza, Ongentys |
| Lundbeck LLC | $814.25 | 2019-2025 | Vyepti, Rexulti |
| Pfizer INC. | $801.00 | 2021-2025 | |
| Lilly USA, LLC | $777.54 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Amneal Pharmaceuticals LLC | $776.83 | 2019-2025 | Rytary, Crexont |
| Emd Serono, INC. | $770.21 | 2019-2025 | Mavenclad |
| Celgene Corporation | $736.57 | 2021-2025 | Zeposia |
| Sunovion Pharmaceuticals INC. | $736.51 | 2019-2022 |
Show all 83 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $712.54 | 2019-2020 | |
| Amgen INC. | $698.46 | 2019-2025 | Uplizna, Aimovig |
| Genzyme Corporation | $616.28 | 2019-2025 | |
| Ge Healthcare | $578.32 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $546.68 | 2020-2025 | Austedo Xr, Austedo, Austedo Xr |
| Mdd US Operations, LLC | $514.93 | 2019-2025 | Gocovri, Apokyn, Qelbree |
| Merz Pharmaceuticals, LLC | $509.86 | 2021-2025 | Xeomin, Inbrija |
| Allergan, INC. | $481.22 | 2019-2022 | |
| Csl Behring | $471.92 | 2019-2025 | Hizentra |
| Kyowa Kirin, INC. | $469.85 | 2019-2025 | Nourianz |
| Tg Therapeutics, INC. | $356.02 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $346.86 | 2019-2025 | Nuplazid, Daybue |
| Janssen Pharmaceuticals, INC | $329.80 | 2019-2023 | Ponvory |
| Genentech USA, INC. | $323.75 | 2019-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Biohaven Pharmaceuticals, INC. | $320.02 | 2020-2021 | |
| Ipsen Biopharmaceuticals, INC | $319.46 | 2019-2025 | Dysport |
| Banner Life Sciences, LLC | $303.55 | 2021-2024 | |
| Avanir Pharmaceuticals, INC. | $292.94 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $254.40 | 2022 | |
| Medtronic, INC. | $230.86 | 2021-2025 | Percept PC Brainsense, Nexframe |
| Grifols USA, LLC | $218.75 | 2019-2025 | Gamunex-C |
| Tanabe Pharma America, INC. | $216.86 | 2019-2025 | Radicava |
| Astrazeneca Pharmaceuticals LP | $191.84 | 2021-2025 | Andexxa, Wainua |
| Greenwich Biosciences, INC. | $169.83 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $169.11 | 2020-2025 | Fycompa |
| Abbott Laboratories | $161.11 | 2019-2024 | Infinity |
| Adamas Pharmaceuticals, INC. | $143.63 | 2019-2021 | |
| Livanova USA, INC. | $140.51 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Upsher-Smith Laboratories LLC | $124.29 | 2019-2021 | |
| Acorda Therapeutics, INC | $115.22 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $115.20 | 2020-2025 | |
| Octapharma USA, INC. | $115.17 | 2022-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Axsome Therapeutics, INC. | $112.73 | 2025 | Symbravo |
| Takeda Pharmaceuticals U.S.A., INC. | $97.72 | 2022-2025 | Hyqvia |
| Boston Scientific Corporation | $91.13 | 2019-2024 | |
| Mallinckrodt Enterprises LLC | $84.11 | 2019 | |
| Argenx US, INC. | $80.34 | 2022 | |
| Portola Pharmaceuticals, LLC | $79.49 | 2019 | |
| Merz North America, INC. | $78.92 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $75.23 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $68.91 | 2020-2024 | |
| Amylyx Pharmaceuticals, INC. | $66.29 | 2023 | Relyvrio |
| Avion Pharmaceuticals | $63.94 | 2022-2023 | Dhivy |
| Neurelis, INC. | $60.98 | 2021-2025 | Valtoco |
| Janssen Biotech, INC. | $60.10 | 2025 | |
| Revance Therapeutics, INC. | $51.96 | 2024-2025 | Daxxify, Daxi |
| Medtronic USA, INC. | $50.09 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $49.85 | 2020 | |
| Cycle Pharmaceuticals INC | $43.68 | 2025 | Bafiertam, Tascenso Odt |
| Impel Pharmaceuticals INC. | $40.03 | 2023 | Trudhesa |
| Neuropace, INC. | $37.94 | 2024 | |
| Merck Sharp & Dohme LLC | $36.03 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $35.94 | 2024 | Ponvory |
| Invivyd INC | $33.02 | 2025 | Pemgarda |
| Averitas Pharma INC. | $30.00 | 2024 | Qutenza |
| Alnylam Pharmaceuticals INC. | $27.39 | 2024 | Amvuttra |
| Corium, LLC | $24.74 | 2022 | |
| Aucta Pharmaceuticals, INC. | $24.74 | 2025 | Motpoly Xr |
| Otsuka America Pharmaceutical, INC. | $23.70 | 2023 | Nuedexta |
| Sumitomo Pharma America, INC. | $20.86 | 2023 | Aptiom |
| Azurity Pharmaceuticals, INC. | $19.21 | 2025 | |
| Bausch Health US, LLC | $19.04 | 2022 | |
| Aquestive Therapeutics, INC. | $18.77 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.72 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $16.12 | 2025 | Lumryz |
| Alfasigma USA, INC. | $15.22 | 2020 | |
| Assertio Therapeutics, INC. | $14.20 | 2020 | |
| Travere Therapeutics, INC. | $1.66 | 2022 |
Drugs and devices associated with these payments
Botox $1,263Qulipta $1,134Kesimpta $985Vumerity $979Ubrelvy $906Tysabri $836Zeposia $648Ultomiris $617Nurtec Odt $596Ingrezza $589Leqembi $566Duopa $455Vyepti $417Zavzpret $412Briumvi $356Rystiggo $344Briviact $279Vyalev $272Xeomin $265Nourianz $256Dysport $246Austedo Xr $230Rytary $227Nuplazid $226Nayzilam $205Inbrija $195Ongentys $184Amyvid $183Crexont $180Hizentra $175Panzyga $167Paxlovid $165Gamunex-C $153Comirnaty $146Gocovri $141Emgality $135Kisunla $132Austedo $129Fycompa $128Vns Therapy Sentiva Model 1000 Generator $119Linzess $118Symbravo $113Radicava $112Bafiertam $109Ocrevus Zunovo $104Infinity $99.23Apokyn $95.37Mavenclad $81.71Radicava Ors $75.07Uplizna $72.25Avonex $67.02Relyvrio $66.29Ocrevus $64.97Andexxa $61.92Zilbrysq $59.86Ponvory $59.84Hyqvia $56.22Soliris $56.18Ztlido $53.86Plegridy $51.16Octagam Immune Globulin (Human) $49.88Percept PC Brainsense $48.74Enspryng $47.87Dhivy $44.89Valtoco $44.64Tascenso Odt $43.68Daybue $41.99Xywav $41.73Trudhesa $40.03Vraylar $39.63Rns Neurostimulator Kit $37.94Epidiolex $36.26Pemgarda $33.02Daxxify $33.00Qutenza $30.00Wainua $28.64Xcopri $27.92Amvuttra $27.39Motpoly Xr $24.74Nuedexta $23.70Rexulti $22.49Nexframe $21.90Qelbree $21.80Vns Therapy $21.77Aptiom $20.86Exservan $19.82Daxi $18.96Reyvow $16.92Lumryz $16.12Aimovig $14.68Mayzent $13.98
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mayank Pathak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.